tradingkey.logo

Microbot Medical Inc

MBOT
查看詳細走勢圖
2.195USD
+0.115+5.53%
交易中 美東報價延遲15分鐘
144.50M總市值
虧損本益比TTM

Microbot Medical Inc

2.195
+0.115+5.53%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+5.53%

5天

-8.92%

1月

+19.95%

6月

-8.92%

今年開始到現在

+95.98%

1年

+125.24%

查看詳細走勢圖

TradingKey Microbot Medical Inc股票評分

單位: USD 更新時間: 2025-12-19

操作建議

Microbot Medical Inc當前公司基本面數據相對謹慎,增長潛力很大。當前估值合理,在生物技術與醫療研究行業排名152/404位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價8.75。中期看,股價處於下降通道。近一個月,市場表現較強,技術面評分較高,但較強的走勢未獲得基本面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Microbot Medical Inc評分

相關信息

行業排名
152 / 404
全市場排名
280 / 4582
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 2 分析師
買入
評級
8.750
目標均價
+270.76%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Microbot Medical Inc亮點

亮點風險
Microbot Medical Inc. is a pre-commercial stage medical technology company. It has developed the single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems. It specializes in the research, design and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, it is developing a fully disposable robot for various endovascular interventional procedures. The LIBERTY Endovascular Robotic Surgical System is designed to maneuver guidewires and over-the-wire devices (such as microcatheters) within the body’s vasculature. It eliminates the need for extensive capital equipment requiring dedicated Cath-lab rooms as well as dedicated staff. Its addressable markets for the LIBERTY Endovascular Robotic Surgical System include the peripheral interventional radiology, interventional cardiology and interventional neuroradiology markets.
估值低估
公司最新PE估值-4.62,處於3年歷史低位
機構減倉
最新機構持股5.08M股,環比減少15.14%
先鋒集團持倉
明星投資者先鋒集團持倉,最新持倉2.34M股
活躍度增加
近期活躍度增加,過去20天平均換手率-0.02

Microbot Medical Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Microbot Medical Inc簡介

Microbot Medical Inc. is a pre-commercial stage medical technology company. It has developed the single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems. It specializes in the research, design and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, it is developing a fully disposable robot for various endovascular interventional procedures. The LIBERTY Endovascular Robotic Surgical System is designed to maneuver guidewires and over-the-wire devices (such as microcatheters) within the body’s vasculature. It eliminates the need for extensive capital equipment requiring dedicated Cath-lab rooms as well as dedicated staff. Its addressable markets for the LIBERTY Endovascular Robotic Surgical System include the peripheral interventional radiology, interventional cardiology and interventional neuroradiology markets.
公司代碼MBOT
公司Microbot Medical Inc
CEOGadot (Harel)
網址http://www.microbotmedical.com/

常見問題

Microbot Medical Inc(MBOT)的當前股價是多少?

Microbot Medical Inc(MBOT)的當前股價是 2.195。

Microbot Medical Inc 的股票代碼是什麼?

Microbot Medical Inc的股票代碼是MBOT。

Microbot Medical Inc股票的52週最高點是多少?

Microbot Medical Inc股票的52週最高點是4.670。

Microbot Medical Inc股票的52週最低點是多少?

Microbot Medical Inc股票的52週最低點是0.960。

Microbot Medical Inc的市值是多少?

Microbot Medical Inc的市值是144.50M。

Microbot Medical Inc的淨利潤是多少?

Microbot Medical Inc的淨利潤為-11.44M。

現在Microbot Medical Inc(MBOT)的股票是買入、持有還是賣出?

根據分析師評級,Microbot Medical Inc(MBOT)的總體評級為買入,目標價格為8.750。

Microbot Medical Inc(MBOT)股票的每股收益(EPS TTM)是多少

Microbot Medical Inc(MBOT)股票的每股收益(EPS TTM)是-0.450。
KeyAI